Level Four Advisory Services LLC Purchases 283 Shares of Eli Lilly and Company $LLY

Level Four Advisory Services LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,726 shares of the company’s stock after purchasing an additional 283 shares during the quarter. Level Four Advisory Services LLC’s holdings in Eli Lilly and Company were worth $5,244,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Brighton Jones LLC increased its stake in Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Covestor Ltd grew its stake in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the period. Kaufman Rossin Wealth LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $242,000. Finally, Momentous Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $225,000. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on LLY shares. Sanford C. Bernstein boosted their price target on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research note on Monday. Daiwa Capital Markets boosted their target price on shares of Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Truist Financial increased their target price on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Finally, Cantor Fitzgerald boosted their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $1,047.50.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,074.94 on Friday. The stock has a 50-day simple moving average of $889.37 and a 200 day simple moving average of $799.23. The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 70.26, a P/E/G ratio of 1.21 and a beta of 0.43. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the prior year, the firm earned $1.18 EPS. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.